August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 08/28/23
1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall StreetThe Motley Fool • 08/24/23
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell DiseaseBusiness Wire • 08/16/23
bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel RevenuesZacks Investment Research • 08/09/23
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational ProgressBusiness Wire • 08/08/23
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial UpdateBusiness Wire • 07/25/23
Top EV Maker Highlights 5 ‘Strong Buy' Stocks Under $10 With Huge Upside Potential24/7 Wall Street • 07/22/23
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mlnReuters • 07/13/23
Down 51% in 2023, Here's Why Bluebird Bio Stock Could Soon Double, Says Wall StreetThe Motley Fool • 06/30/23
bluebird bio shares positioned to pop ‘significantly higher' as FDA accepts sickle cell therapy applicationProactive Investors • 06/21/23
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive EventsBusiness Wire • 06/21/23